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Histone modification and DNA methylation are criticalevents that determine gene expression. Histone deacety-
lases (HDAC) render several critical genes transcriptionally
inactive by conferring a “hyperwound” configuration. HDAC
inhibition leads to unwinding of the DNA and makes it
available to the transcriptional machinery for expression of a
number of regulatory genes.1 Because cancer is characterized
by several abnormal genetic marks, HDAC inhibitors have
emerged as novel agents for the treatment of cancer. By
affecting a number of important genes, HDAC inhibitors
cause cell cycle arrest, induce cell differentiation, reverse cell
transformation, and restrain tumor growth. In addition to the
effect on gene transcription, HDAC inhibitors also act di-
rectly at the protein level to alter a number of important
cellular functions. A number of HDAC inhibitors are cur-
rently under development. Vorinostat, a hydroxamic acid
derivative, is approved by the US FDA for the treatment of
cutaneous T-cell lymphoma. A number of presentations at the
Targeted Therapies Meeting in Santa Monica 2011 focused
on recent developments and promising new treatment strate-
gies with HDAC inhibitors in non-small cell lung cancer
(NSCLC).
Summary of Presentations
Dr. Eric Haura discussed the rationale for targeting
HDAC in patients with NSCLC. His talk highlighted the
mechanistic insights gained in recent years regarding HDAC
inhibitors and set the stage for discussions on novel combi-
nations and approaches to improve the outcome for patients
with advanced NSCLC.
Vorinostat
Vorinostat is an orally administered agent that has
demonstrated modest activity as monotherapy in a variety of
solid organ malignancies. In a randomized phase II study by
Ramalingam et al.2 for advanced NSCLC patients, carbopla-
tin and paclitaxel were given in combination with vorinostat
or placebo. Promising response rate, PFS, and survival were
noted with the addition of vorinostat, although toxicity was
also higher for the combination. These observations were
aligned with the efficacy noted in a preceding phase I study.3
A confirmatory study, however, failed to demonstrate effi-
cacy advantage with vorinostat. Dr. Chandra Belani described
an alternate approach to improve the therapeutic index of the
regimen by altering the dose and schedule of vorinostat and
is leading an NCI-sponsored phase II study. In early phase
studies, objective responses were noted in patients with
malignant pleural mesothelioma with vorinostat as mono-
therapy. Subsequently, a randomized phase III study of vori-
nostat versus placebo has been completed for second-line
therapy for mesothelioma. The results of this study are
anticipated later this year.
Entinostat
Entinostat is a selective HDAC inhibitor that has a long
half-life. It is given either weekly or bi-weekly and has
demonstrated a good safety profile in early phase studies.
HDAC inhibitors can reverse the epithelial-to-mesenchymal
transformation (EMT) and restore sensitivity to erlotinib in
preclinical models. Jotte et al. reported the results of a
randomized phase II study of erlotinib given in combination
with entinostat or placebo for second-line therapy for ad-
vanced NSCLC. Although there were no differences in effi-
cacy for the overall patient population, patients with high
E-cadherin expression in their tumors experienced a higher
median survival (9.4 versus 5.4 m) with entinostat.4 Because
E-cadherin is a marker of EMT, it could be used to select a
sensitive subgroup of patients for the combination regimen.
Another novel approach using the combination of en-
tinostat with a demethylating agent was discussed by Dr.
Rosalyn Juergens. In cancer cells, the transcription com-
plexes are blocked from reaching the promoter because of
histone deaceylation.5 Therefore, the combination of a
HDAC and DNA methylation inhibitor can induce expression
of silenced genes relevant to restore checkpoints and regula-
tory functions. Promising anecdotes of objective responses
were noted in a phase II study with entinostat and 5-azacyt-
idine in a cohort of 32 patients with advanced NSCLC. Based
on this, a randomized phase II study of entinostat in combi-
nation with 5-azacitidine versus standard therapy is being
conducted in patients with resected stage IA or IB NSCLC.
Romidepsin
Romidpesin is a novel HDAC inhibitor that is different
from the hydoxamate derivatives in having a cyclic peptide
structure. In preclinical studies, romidepsin has demonstrated
selectivity to NSCLC cells and enhanced the effects of
erlotinib. Dr. David Gerber described an ongoing phase I/II
study of romidepsin in combination with erlotinib for patients
with advanced NSCLC. Two dose cohorts of romidepsin
have been studied (8 and 10 mg/m2). The combination has
been tolerated well, and disease stabilization was noted in
four of six patients. This study is ongoing.
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LBH589
LBH589 is a pan-HDAC inhibitor that has demon-
strated preclinical anticancer effects in NSCLC models. Dr.
Jhanelle Gray described an ongoing phase I study of LBH589
in combination with erlotinib for patients with advanced
NSCLC. LBH589 is given orally twice a week to sequential
cohorts of patients with a starting dose of 20 mg. A total of
40 patients have been enrolled to the study, and the combi-
nation regimen has been tolerated well. One patient experi-
enced a partial response and nine patients had disease stabi-
lization. The recommended doses for the combination are
erlotinib at 100 mg/d and LBH589 at 20 mg twice a week.
CUDC-101
Dr. Samir Witta described a novel compound, CUDC-
101, that integrates a hydroxamic acid HDAC-inhibiting
moiety into a quinazoline receptor tyrosine kinase inhibition
pharmacopore, thereby designed to achieve dual inhibition of
HDAC and EGFR. In preclinical studies, CUDC-101 exhibits
immediate and stable inhibition of receptor tyrosine kinase
and downstream Akt signaling. In addition, cancer cells
harboring MET amplification are sensitive to CUDC-101. In
an ongoing phase I study, CUDC-101 has been tolerated well
at doses of 75 to 275 mg/m2 as an intravenous infusion given
on 5 consecutive days every 2 weeks. The most common
treatment-related toxicity was fatigue. A patient with gastric
cancer had a confirmed partial response and many patients
had disease stabilization. A phase IB expansion study is
currently underway with CUDC-101 for patients with a
refractory gastric, head and neck, and NSCLC cancers.
Future Directions
HDAC inhibitors have demonstrated activity in a vari-
ety of hematological malignancies but only modest effects in
patients with solid organ tumors. It is clear that novel com-
bination approaches are required to improve the therapeutic
utility of HDAC inhibitors, with the exception of mesotheli-
oma, that seems to be sensitive to vorinostat monotherapy.
Given the effects of HDAC inhibitors on a plethora of
important and relevant targets in NSCLC, preclinical ratio-
nale to combine them with pemetrexed, platinum, taxanes,
antiangiogenic agents, and EGFR inhibitors have been dem-
onstrated.6 Identification of optimal predictive biomarkers
remains an important avenue for further research. The com-
bination of HDAC inhibition with radiotherapy is another
therapeutic opportunity that is well-supported by preclinical
data.7 The results with HDAC inhibitors have been mixed in
NSCLC so far, but with more rigorous efforts on patient
selection methods, it is hoped that this group of anticancer
agents will find a prominent place in the therapeutic arma-
mentarium.
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